A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Required: CD20 expression

a histologically-confirmed hematological malignancy that is expected to express cluster of differentiation (CD)20

Must have received: any prior treatment regimen

relapse after or failure to respond to at least one prior treatment regimen

Cannot have received: systemic immunotherapeutic agents (radio-immunoconjugates, antibody-drug conjugates, immune/cytokines, monoclonal antibodies, anti-CTLA4, anti-PD1, anti-PDL1)

Exception: within 4 weeks or five half-lives of the drug, whichever is shorter, before obinutuzumab infusion on Cycle 1 Day -7

Prior treatment with systemic immunotherapeutic agents, including, but not limited to, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines and monoclonal antibodies (e.g., anti-CTLA4, anti-PD1 and anti-PDL1) within 4 weeks or five half-lives of the drug, whichever is shorter, before obinutuzumab infusion on Cycle 1 Day -7

Cannot have received: obinutuzumab-containing regimen (obinutuzumab)

Exception: documented refractoriness

Documented refractoriness to an obinutuzumab-containing regimen

Cannot have received: standard radiotherapy

Exception: within 4 weeks prior to obinutuzumab infusion

Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent, including chimeric antigen receptor therapy (CAR-T) within 4 weeks prior to obinutuzumab infusion

Cannot have received: chemotherapeutic agent

Exception: within 4 weeks prior to obinutuzumab infusion

Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent, including chimeric antigen receptor therapy (CAR-T) within 4 weeks prior to obinutuzumab infusion

Cannot have received: investigational anti-cancer agent

Exception: within 4 weeks prior to obinutuzumab infusion

Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent, including chimeric antigen receptor therapy (CAR-T) within 4 weeks prior to obinutuzumab infusion

Cannot have received: CAR-T cell therapy

Exception: within 4 weeks prior to obinutuzumab infusion

Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent, including chimeric antigen receptor therapy (CAR-T) within 4 weeks prior to obinutuzumab infusion

Cannot have received: allogeneic stem cell transplantation

Prior allogeneic stem cell transplantation (SCT)

Cannot have received: autologous stem cell transplantation

Exception: within 100 days prior to obinutuzumab infusion

Autologous SCT within 100 days prior to obinutuzumab infusion